Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Renal Cell × Tablets × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 17 Neoplasms 9 Polycystic Ovary Syndrome 7 Multiple Myeloma 4 Vomiting 3 Prostatic Neoplasms 3 Neoplasm Metastasis 3 Melanoma 3 Leukemia, Myeloid, Acute 3 Head and Neck Neoplasms 3 Endometrial Neoplasms 3 Triple Negative Breast Neoplasms 2 Solid Tumors 2 Recurrence 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Obesity 2 Nausea 2 Lung Neoplasms 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Leukemia, B-Cell 2 Leukemia 2 Leiomyoma 2 Insulin Resistance 2 Inflammation 2 Infertility, Female 2 Glioblastoma 2 Colorectal Neoplasms 2 Cardiotoxicity 2 Carcinoma, Non-Small-Cell Lung 2 Weight Gain 1

Interventions

Nivolumab 122 Sunitinib 113 pembrolizumab 110 Sorafenib 69 Everolimus 63 cabozantinib 62 Bevacizumab 61 pazopanib 58 Ipilimumab 52 Axitinib 52 aldesleukin 46 Magnetic Resonance Spectroscopy 40 Cyclophosphamide 34 Interferon-alpha 32 Interleukin-2 31 Specimen Handling 29 Radiosurgery 29 lenvatinib 28 temsirolimus 25 atezolizumab 22 belzutifan 21 fludarabine phosphate 18 avelumab 18 Gemcitabine 18 Interferon alpha-2 16 Biopsy 16 fludarabine 15 Nephrectomy 15 Radiotherapy 14 Paclitaxel 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01865747 2021-04-27

METEOR

Exelixis

Phase 3 Completed

658 enrolled 15 charts

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡